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In this issue of Blood, Inaba et al review the challenges and questions to be
answered in the molecular and functional dissection of loss of chromosome 7
(monosomy 7 [27]) and deletion of a segment of the long arm (del(7q)) found
in patients with various syndromes involving the myeloid blood cell lineage.1
Large hemizygous deletions that may be
drivers of cancer are found in various types
of tumors. 27 and del(7q) are recurrent
cytogenetic abnormalities that are strongly
associated with myelodysplastic syndrome
(MDS) and acute myeloid leukemia (AML)
with adverse outcome (eg, in AML with
chromosome 3q26 abnormalities and ab-
errant EVI1 expression).2 They also occur
in cases of MDS and AML that arise in a
number of other contexts, including oc-
cupational exposure to mutagens, follow-
ing aplastic anemia, or in certain germ line
predisposition syndromes.
The similar biological and clinical fea-
tures of patients with different ante-
cedent risk factors raises the question
whether the alteration of 1 common
gene on 7q is particularly responsible for
the pathogenesis of all of these myeloid
disorders. Cytogenetic and ﬂuorescent
in situ hybridization analyses identiﬁed
2 commonly deleted regions (CDRs) in
patients with myeloid disorders with
chromosome 7 loss or del(7q), 1 located in
band q22 accounting for most cases and a
second segment in bands q32-33. These
data are consistent with the hypothesis
that recessive mutations, which inactivate
tumor suppressor genes within these CDRs,
contribute to leukemogenesis in patients
with27 or del(7q). Targeted sequencing
of candidate myeloid tumor suppressor
genes located within a 2.5-Mb 7q22 CDR
delineated by Le Beau et al and recent
comprehensive genomic analyses of clini-
cal specimens implicate a haploinsufﬁcient
role of 7q22deletions in leukemogenesis.1,3
Consistent with the proposed mechanism,
biallelic inactivation of any 7q gene is rare
inMDSpatients with27/del(7q), and haplo-
insufﬁciency seems to be the pathogenic
mechanism. Given the number of genes
involved and also various biallelic or mon-
oallelic mutations, as also reviewed in
Inaba et al, the question remains if the
pathophysiology is more complex than
just haploinsufﬁciency for 1 or multiple
genes. Moreover, it is possible that not just
a single mechanism can explain the effects
caused by either 27 or 7q2 aberrations in
the different types of myeloid disorders.
CDRs provide a starting place for the
search for critical genes in the clinical
phenotype and disease pathogenesis. In
del(5q) MDS, a functional RNA interfer-
ence screen identiﬁed RPS14 as a criti-
cal gene responsible for pathognomonic
anemia and the erythroid differentiation
defect.4 Additionally, murine models of
heterozygous inactivation of candidate
genes provided a critical demonstration
of the effects of haploinsufﬁciency for a
gene in vivo in del(5q) MDS.5,6
Inaba et al describe in their review the
various efforts made in 27/del(7q) over
the decades, which ultimately led re-
searchers to accept that the identiﬁcation
of CDRs as the ﬁrst approach to de-
termine classical-type recessive tumor
suppressors, was not effective. This most
likely reﬂects the multitude of potential
myeloid tumor suppressor genes that
may act in a haploinsufﬁcient manner,
driving the development of myeloid
disorders. In contrast to del(5q), where
the focus has been on identifying the
central pathogenic genes for the distinct
clinical phenotype, studies in 27/del(7q)
have focused on directly analyzing the
biological effects of large segmental
loss of the chromosome.7,8 These studies
make investigators wonder whether com-
binatorial haploinsufﬁciency of many genes
on chromosome 7 is responsible for the
aberrant behavior of hematopoietic stem
and progenitor cells (HSPCs).
Inaba et al describe in detail genes lo-
cated at chromosome 7 that may play
a critical role in the disease phenotype
and pathogenesis and discuss their role
in myeloid malignancies: SAMD9 and
SAMD9L, EZH2, MLL3, and CUX1. A
recent study demonstrated that hetero-
zygous SAMD9L missense mutations
are found in patients of familial MDS
(reviewed in Inaba et al). Inherited can-
cer syndromes have greatly contributed
to basic concepts of tumor biology (eg,
leading to the “2-hit” hypothesis by
Knudson and providing the concept of
“multistep” carcinogenesis by Vogelstein
and Kinzler). Importantly, a recent study
on childhood MDS demonstrated that
mutated SAMD9L alleles were lost in
MDS cells. Thus, instead of representing
malignancy-predisposing mutations of
tumor suppressor genes in the classi-
cal sense, gain-of-function mutations in
SAMD9 or SAMD9L together provide the
ﬁrst human examples of “adaptation by
aneuploidy.” This means that HSPCs that
eliminate SAMD9 or SAMD9L gain-of-
function mutations through aneuploidy
gain a competitive advantage, simulta-
neously predisposing toMDS (see Figure 2
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in Inaba et al). This represents an intriguing
new paradigm in malignant transforma-
tion and also adds additional complexity
to dissecting the disease pathogenesis in
27/del(7q).
Based on their literature review, Inaba
et al hypothesize that27/del(7q) can be
an early event in HSPCs. They picture 2
scenarios: (1) an unperturbed environ-
ment and (2) a perturbed environment.
They reason that in scenario 1 (in a
normal HSPC and normal bone mar-
row), the 27/del(7q) clone has a rela-
tive growth advantage over normal
HSPCs in the bone marrow and se-
quentially acquires secondary genetic
or epigenetic events. In scenario 2,
during bone marrow failure, hemato-
poietic stem cells are embedded in an
inﬂammatory environment (cytokines).
Here, aneuploid stem cells with haplo-
insufﬁciency of multiple genes impli-
cated in the regulation of DNA damage
checkpoints, the cell cycle, and apoptosis
facilitate the accumulation of additional
mutations and aberrant expansion, ulti-
mately leading to leukemogenesis.
Notably, data obtained so far are correla-
tive. Dissecting how abnormalities affecting
large chromosomal regions mechanistically
give rise to distinct cancers is challenging.
Future efforts need to focus on validating
ﬁndings in greater numbers of patients, in
addition to identifying more deﬁnitive
causal relationships between genes and
function. Additional single-cell studies and
gene editing using CRISPR/Cas9 in HSPCs
will be instrumental in delineating how dis-
tinct chromosomal abnormalities interact
with additional genemutations todetermine
the stepwise transformation to leukemia.
These studies will also help in dissecting
gene targets for targeted therapies.
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Lipid metabolism in
terminal erythropoiesis
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In this issue of Blood, Huang et al have provided evidence that altered lipid
metabolism is critical for terminal erythropoiesis. A key role is proposed for
the PHOSPHO1 gene product, a phosphocholine phosphatase. PHOSPHO1
knockouts (KOs) showed reduced erythroblast proliferation and enucleation
in bothmice and human erythroid tissues, apparently through energydepletion
mediated via inhibition of oxidative phosphorylation of fatty acids and reduced
adenosine triphosphate (ATP) production in late glycolysis. This work em-
phasizes that altered expression of genes involving lipid metabolism are im-
portant during late red cell maturation.1
The mature red cell is unique. Although
highly specialized for gas transport, it is
much more than an inert receptacle for
hemoglobin, with many surprisingly so-
phisticated properties. Among these,
the subtle control of glucose metabo-
lism, cytoskeletal integrity, andmembrane
permeability by oxygen tension has re-
cently been elucidated.2 During matu-
ration, the developing red cell must both
proliferate and undergo considerable
modiﬁcations to acquire the necessary
properties to survive in the circulatory
system, where it lacks the ability to syn-
thesize proteins de novo while experi-
encing profound challenges such as
repeated episodes of shear and oxidative
stress. Many important changes occur
during later erythrogenesis, including loss
of the nucleus, shedding of surface
markers, establishment of the ﬁnal surface
area/volume ratio, and establishment of a
robust but malleable cytoskeleton.3
Our understanding of the processes occur-
ring during erythropoiesis remains partial.
Much is knownabout globingene switching,
which is of particular relevance to a num-
ber of the common hemoglobinopathies.4
Some other nonglobin protein changes
have also been well studied. These in-
clude accumulation of cytoskeletal ele-
ments with condensation of spectrin,
increased expression of band 3, and ac-
quisition of other requisite membrane
transporters.3 Mutations in these proteins
are relatively rare, but are sometimes as-
sociated with hemolytic anemia and ir-
regularities in red cell shape or volume
(such as stomatocytes and spherocytes).5
Elucidation of their molecular causes
continues to improve our understanding
of red cell physiology.
Diseases involving altered lipid metabo-
lism are arguably less well characterized.
As for those involving protein transporters,
they can be secondary (ie, subsequent
to other diseases). An obvious exam-
ple here is loss of aminophospholipid
asymmetry in a number of hemoglo-
binopathies such as sickle cell disease.
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